Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Dr. Marius Ringelstein, a neurologist from Heinrich Heine University specializing in Neuromyelitis Optica Spectrum Disorders (NMOSD), and Dr. Ilya Ayzenberg from Rory University discuss the use of Eculizumab in treating NMOSD. They emphasize the drug's effectiveness and safety, particularly concerning vaccination against meningococcal infections for patients. The conversation highlights vaccination protocols and the timing of treatments, as well as the promising alternative of Ravulizumab for less frequent dosing. Practical insights shape their review of patient-centered care.